» Articles » PMID: 11004090

Matrix Metalloproteinases and Their Natural Inhibitors in Fibrovascular Membranes of Proliferative Diabetic Retinopathy

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 2000 Sep 27
PMID 11004090
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To examine epiretinal membranes of proliferative diabetic retinopathy (PDR) for the presence of selective matrix metalloproteinases (MMPs) and their natural inhibitors (TIMPs), in order to determine whether neovascularisation and fibrosis, characteristic of this complication of diabetes mellitus, are associated with specific anomalies of MMP or TIMP expression.

Methods: The presence of selected MMPs and TIMPs was investigated in 24 fibrovascular epiretinal membranes of PDR, and the findings compared with that observed in 21 avascular epiretinal membranes of proliferative vitreoretinopathy (PVR) and five normal retinas. Specimens were examined for deposition of interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), gelatinase A (MMP-2), gelatinase B (MMP-9), and three tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2, and TIMP-3).

Results: The results showed that unlike normal retina, which constitutively expresses MMP-1 and TIMP-2, a large proportion of PDR membranes (> 62%) stained for MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2, and TIMP-3. There were no differences in the expression of these molecules when compared with PVR membranes. A characteristic staining for MMP-9 was observed within the perivascular matrix of PDR membranes, and there was a significant increase in TIMP-2 expression by PDR membranes (p= 0.036) when compared with PVR membranes.

Conclusions: The findings that MMPs involved in degradation of fibrovascular tissue matrix, as well as TIMP-1 and TIMP-2, are found in a large proportion of PDR membranes, and that their expression does not differ from that of PVR membranes, suggest the existence of common pathways of extracellular matrix degradation in pathological processes leading to retinal neovascularisation and fibrosis.

Citing Articles

Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis.

Liu D, Meng Z, Jin C, Chen F, Pu L, Wu Z Invest Ophthalmol Vis Sci. 2025; 66(3):10.

PMID: 40042877 PMC: 11892531. DOI: 10.1167/iovs.66.3.10.


Plasma matrix metalloproteinases and tissue inhibitors of metalloproteinases explored in relation to the severity and progression of diabetic retinopathy in patients with type 1 diabetes: baseline and prospective analyses.

Hector S, Thulesius H, Thunander M, Hillman M, Landin-Olsson M, Melin E BMJ Open Ophthalmol. 2024; 9(1).

PMID: 38991835 PMC: 11243131. DOI: 10.1136/bmjophth-2023-001583.


Single-Cell RNA Sequencing Reveals Transcriptional Signatures and Cell-Cell Communication in Diabetic Retinopathy.

Li M, Peng Y, Pang L, Wang L, Li J Endocr Metab Immune Disord Drug Targets. 2024; 24(14):1651-1663.

PMID: 38988068 DOI: 10.2174/0118715303286652240214110511.


Proteomic study of vitreous in proliferative diabetic retinopathy patients after treatment with aflibercept: a quantitative analysis based on 4D label-free technique.

Feng T, Gao X, Liang A, Zhao B, He G, Chen S Int J Ophthalmol. 2024; 17(4):676-685.

PMID: 38638258 PMC: 10988087. DOI: 10.18240/ijo.2024.04.11.


Matrix Metalloproteinase-2 () and-9 () Gene Variants and Microvascular Complications in Type 2 Diabetes Patients.

Andjelic J, Radojkovic D, Nikolic A, Rakicevic L, Babic T, Jelic D Balkan J Med Genet. 2023; 25(1):35-40.

PMID: 36880042 PMC: 9985363. DOI: 10.2478/bjmg-2022-0001.


References
1.
Jerdan J, Pepose J, Michels R, Hayashi H, De Bustros S, Sebag M . Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology. 1989; 96(6):801-10. DOI: 10.1016/s0161-6420(89)32818-1. View

2.
Gilbert C, Hiscott P, Unger W, Grierson I, McLeod D . Inflammation and the formation of epiretinal membranes. Eye (Lond). 1988; 2 Suppl:S140-56. DOI: 10.1038/eye.1988.140. View

3.
Alexander J, Bradley J, GABOUREL J, Acott T . Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1990; 31(12):2520-8. View

4.
Taylor C, Thompson J, Weiss J . Matrix integrity and the control of angiogenesis. Int J Radiat Biol. 1991; 60(1-2):61-4. DOI: 10.1080/09553009114551551. View

5.
Franks W, Limb G, Stanford M, Ogilvie J, Wolstencroft R, CHIGNELL A . Cytokines in human intraocular inflammation. Curr Eye Res. 1992; 11 Suppl:187-91. DOI: 10.3109/02713689208999531. View